Quick Answer
Forte Biosciences, Inc. reported Total Revenue of $36.0 thousand for fiscal year 2019.
Forte Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Revenue (ASC 606) | — | — | — | — | — | — |
| Net Income | -$69.38M -95.5% |
-$35.48M -12.7% |
-$31.48M -126.8% |
-$13.88M +36.1% |
-$21.71M +53.3% |
-$46.49M -1042.5% |
| Diluted EPS | -$4.71 +61.3% |
-$12.17 +51.2% |
-$24.92 -3015.0% |
-$0.80 +48.4% |
-$1.55 | — |
| Total Assets | $82.78M +34.5% |
$61.56M +57.9% |
$38.98M -7.2% |
$42.00M -3.0% |
$43.31M -29.3% |
$61.24M +699.7% |
| Cash and Equivalents | $76.96M +246.0% |
$22.24M -40.1% |
$37.12M -9.7% |
$41.10M -2.2% |
$42.04M -28.5% |
$58.77M +746.9% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $60.99M +16.2% |
$52.48M +48.6% |
$35.31M -9.0% |
$38.82M -6.6% |
$41.55M -29.6% |
$58.98M +1336.7% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$70.66M -93.0% |
-$36.60M -12.7% |
-$32.49M -133.8% |
-$13.90M +35.3% |
-$21.49M +53.6% |
-$46.28M -1038.8% |
| Shares Outstanding | 12.95M +102.5% |
6.39M +339.9% |
1.45M -93.1% |
21.00M +42.3% |
14.75M +15.0% |
12.83M +508.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2019 | $9.0K | -100.0% | +0.0% |
| Revenue (ASC 606) | September 30, 2019 | $9.0K | -100.0% | +0.0% |
| Net Income | September 30, 2025 | -$17.68M | -110.7% | -57.2% |
| Diluted EPS | September 30, 2025 | -$0.99 | +78.2% | -3.1% |
| Total Assets | September 30, 2025 | $97.09M | +441.0% | -9.9% |
| Cash and Equivalents | September 30, 2025 | $93.41M | +470.9% | -12.0% |
| Long-Term Debt | June 30, 2019 | $22.08M | -14.8% | -8.5% |
| Stockholders Equity | September 30, 2025 | $84.10M | +797.9% | -14.7% |
| R&D Expense | March 31, 2020 | $3.14M | -74.7% | -76.4% |
| Operating Income | September 30, 2025 | -$18.38M | -113.0% | -58.8% |
| Shares Outstanding | September 30, 2025 | 12.52M | +757.8% | +2.0% |
- Forte Biosciences, Inc. reported Total Revenue of $36.0 thousand for fiscal year 2019.
- Forte Biosciences, Inc. showed a decrease of -99.8% in Total Revenue compared to the prior fiscal year.
- Forte Biosciences, Inc. reported Revenue (ASC 606) of $36.0 thousand for fiscal year 2019.
- Forte Biosciences, Inc. showed a decrease of -99.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Forte Biosciences, Inc. reported Net Income of -$69.38 million for fiscal year 2025.
- Forte Biosciences, Inc. showed a decrease of -95.5% in Net Income compared to the prior fiscal year.
- Forte Biosciences, Inc. reported Diluted EPS of $4.71 per share (loss) for fiscal year 2025.
- Forte Biosciences, Inc. showed an increase of +61.3% in Diluted EPS compared to the prior fiscal year.
- Forte Biosciences, Inc. reported Total Assets of $82.78 million for fiscal year 2025.
- Forte Biosciences, Inc. showed an increase of +34.5% in Total Assets compared to the prior fiscal year.
- Forte Biosciences, Inc. reported Cash and Equivalents of $76.96 million for fiscal year 2025.
- Forte Biosciences, Inc. showed an increase of +246.0% in Cash and Equivalents compared to the prior fiscal year.
- Forte Biosciences, Inc. reported Long-Term Debt of $26.20 million for fiscal year 2018.
- Forte Biosciences, Inc. showed an increase of +622.8% in Long-Term Debt compared to the prior fiscal year.
- Forte Biosciences, Inc. reported Stockholders Equity of $60.99 million for fiscal year 2025.
- Forte Biosciences, Inc. showed an increase of +16.2% in Stockholders Equity compared to the prior fiscal year.
- Forte Biosciences, Inc. reported R&D Expense of $45.30 million for fiscal year 2019.
- Forte Biosciences, Inc. showed a decrease of -11.3% in R&D Expense compared to the prior fiscal year.
- Forte Biosciences, Inc. reported Operating Income of -$70.66 million for fiscal year 2025.
- Forte Biosciences, Inc. showed a decrease of -93.0% in Operating Income compared to the prior fiscal year.
- Forte Biosciences, Inc. reported Shares Outstanding of 12.95 million shares for fiscal year 2025.
- Forte Biosciences, Inc. showed an increase of +102.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: